Ustekinumab 90 mg

DRUG13 trials

Sponsors

Centocor, Inc., Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Pharmaceutical K.K., Helwan University

Conditions

Arthritis, PsoriaticAxial SpondyloarthritisBehcet's Syndrome, Intestinal TypeCrohn DiseaseDermatomyositisLupus Erythematosus, SystemicMyelodysplastic SyndromePlaque Psoriasis

Phase 2

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease

CompletedNCT00265122

Centocor, Inc.Crohn Disease

Start: 2004-04-30End: 2006-10-31Updated: 2014-02-13

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

CompletedNCT01389973

Janssen Research & Development, LLCPrimary Biliary Cirrhosis

Start: 2011-09-30End: 2013-06-30Updated: 2016-06-20

Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome

CompletedNCT07582991

Liu TianBehcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome

Start: 2024-03-24End: 2026-02-23Updated: 2026-05-13

Phase 3

A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis

CompletedNCT01009086

Janssen Research & Development, LLCArthritis, Psoriatic

Start: 2009-12-31End: 2013-05-31Updated: 2015-03-03

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

CompletedNCT01077362

Janssen Research & Development, LLCArthritis, Psoriatic

Start: 2010-03-31End: 2012-11-30Updated: 2014-02-27

A Study of Ustekinumab to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

CompletedNCT01550744

Janssen Biotech, Inc.Psoriasis

Start: 2012-03-31End: 2015-07-31Updated: 2017-02-09

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

TerminatedNCT02437162

Janssen Research & Development, LLCAxial Spondyloarthritis

Start: 2015-09-03End: 2017-09-06Updated: 2025-04-29

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

TerminatedNCT02438787

Janssen Research & Development, LLCAxial Spondyloarthritis

Start: 2015-07-31End: 2017-08-31Updated: 2025-04-29

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

CompletedNCT02698475

Janssen Research & Development, LLCPsoriasis

Start: 2016-05-31End: 2020-10-31Updated: 2021-11-01

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

TerminatedNCT03517722

Janssen Research & Development, LLCLupus Erythematosus, Systemic

Start: 2018-04-16End: 2020-11-05Updated: 2025-04-29

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

TerminatedNCT03981744

Janssen Pharmaceutical K.K.Dermatomyositis, Polymyositis

Start: 2019-07-26End: 2022-07-12Updated: 2025-04-29

Unknown Phase

A Direct Head-to-head Comparison of Ustekinumab With Infliximab for the Treatment of Ulcerative Colitis

Active, not recruitingNCT06786507

Helwan UniversityUlcerative Colitis (UC)

Start: 2025-05-15End: 2027-12-12Target: 100Updated: 2026-09-17

ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar

RecruitingNCT06997055

Celltrion HealthCare FranceCrohn Disease, Plaque Psoriasis

Start: 2025-03-17End: 2027-12-31Target: 225Updated: 2025-05-30

Related Papers

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.

2024-08-092 citations

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.

2024-08-0118 citations

Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments

RMD Open2023-08-016 citations

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials

Advances in Therapy2023-03-3015 citations

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.

2022-10-1249 citations

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations

Pediatric Drugs2022-09-2815 citations

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

Inflammatory Bowel Diseases2020-09-23112 citations

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials

RMD Open2020-02-0157 citations

03 Targeting interleukin 12/23

2019-09-01

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Drug Safety2019-02-08114 citations

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

2018-06-26268 citations

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).

2016-04-20114 citations

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

2013-06-13562 citations